JP6865160B2 - 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化 - Google Patents

正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化 Download PDF

Info

Publication number
JP6865160B2
JP6865160B2 JP2017512293A JP2017512293A JP6865160B2 JP 6865160 B2 JP6865160 B2 JP 6865160B2 JP 2017512293 A JP2017512293 A JP 2017512293A JP 2017512293 A JP2017512293 A JP 2017512293A JP 6865160 B2 JP6865160 B2 JP 6865160B2
Authority
JP
Japan
Prior art keywords
bone marrow
days
environment
infiltrating lymphocytes
mil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017512293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527286A (ja
JP2017527286A5 (https=
Inventor
イヴァン エム． ボレロ，
イヴァン エム． ボレロ，
キンバリー エー． ヌーナン，
キンバリー エー． ヌーナン，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2017527286A publication Critical patent/JP2017527286A/ja
Publication of JP2017527286A5 publication Critical patent/JP2017527286A5/ja
Priority to JP2021063957A priority Critical patent/JP7197213B2/ja
Application granted granted Critical
Publication of JP6865160B2 publication Critical patent/JP6865160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017512293A 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化 Expired - Fee Related JP6865160B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021063957A JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045782P 2014-09-04 2014-09-04
US62/045,782 2014-09-04
US201562186040P 2015-06-29 2015-06-29
US62/186,040 2015-06-29
PCT/US2015/048536 WO2016037054A1 (en) 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021063957A Division JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Publications (3)

Publication Number Publication Date
JP2017527286A JP2017527286A (ja) 2017-09-21
JP2017527286A5 JP2017527286A5 (https=) 2018-10-11
JP6865160B2 true JP6865160B2 (ja) 2021-04-28

Family

ID=55440392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512293A Expired - Fee Related JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化
JP2021063957A Active JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021063957A Active JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Country Status (13)

Country Link
US (7) US9687510B2 (https=)
EP (2) EP3922254A1 (https=)
JP (2) JP6865160B2 (https=)
KR (1) KR20170067751A (https=)
CN (1) CN107109364A (https=)
AU (2) AU2015311761B2 (https=)
CA (1) CA2959994C (https=)
DK (1) DK3188740T3 (https=)
ES (1) ES2877108T3 (https=)
IL (2) IL250746B (https=)
MX (1) MX391017B (https=)
PT (1) PT3188740T (https=)
WO (1) WO2016037054A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US9687510B2 (en) * 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CA2991040A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric receptors therapy
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
EP3735256A4 (en) 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
WO2020198031A1 (en) * 2019-03-22 2020-10-01 Windmil Therapeutics Inc. Lung cancer specific marrow infiltrating lymphocytes and uses thereof
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
WO2025160242A1 (en) * 2024-01-23 2025-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of generating tils from cerebro spinal fluid for leptomeningeal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3243600A (en) 1999-02-23 2000-09-14 Kathleen S. Carswell Improved method of culturing t cells
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
WO2008147482A2 (en) * 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
BR112014007947A2 (pt) 2011-10-03 2017-04-18 Univ Los Andes método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
JP2014090678A (ja) * 2012-11-01 2014-05-19 Ito En Ltd 容器詰野菜汁及び／又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び／又は果汁含有飲料の呈味劣化防止方法
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
EP3735256A4 (en) * 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Also Published As

Publication number Publication date
IL250746A0 (en) 2017-04-30
PT3188740T (pt) 2021-06-23
AU2015311761A1 (en) 2017-04-06
KR20170067751A (ko) 2017-06-16
WO2016037054A1 (en) 2016-03-10
IL276347B (en) 2021-10-31
US10406178B2 (en) 2019-09-10
EP3188740A4 (en) 2018-05-16
JP2017527286A (ja) 2017-09-21
MX2017002852A (es) 2017-05-30
US11406666B2 (en) 2022-08-09
US20230000919A1 (en) 2023-01-05
US9687510B2 (en) 2017-06-27
JP7197213B2 (ja) 2022-12-27
AU2021200648A1 (en) 2021-03-04
US20170266232A1 (en) 2017-09-21
JP2021104048A (ja) 2021-07-26
US20170258838A1 (en) 2017-09-14
EP3188740B1 (en) 2021-04-14
ES2877108T3 (es) 2021-11-16
US20160331781A1 (en) 2016-11-17
AU2015311761B2 (en) 2020-11-12
US11160830B2 (en) 2021-11-02
CA2959994A1 (en) 2016-03-10
US20220016172A1 (en) 2022-01-20
US20190298768A1 (en) 2019-10-03
US10172887B2 (en) 2019-01-08
EP3922254A1 (en) 2021-12-15
EP3188740A1 (en) 2017-07-12
DK3188740T3 (da) 2021-06-07
US20190350982A1 (en) 2019-11-21
MX391017B (es) 2025-03-21
CN107109364A (zh) 2017-08-29
IL276347A (en) 2020-09-30
IL250746B (en) 2020-08-31
CA2959994C (en) 2023-04-11

Similar Documents

Publication Publication Date Title
JP6865160B2 (ja) 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化
Fang et al. Advances in NK cell production
Childs et al. Bringing natural killer cells to the clinic: ex vivo manipulation
Kang et al. Anti-CD137 suppresses tumor growth by blocking reverse signaling by CD137 ligand
US20030134415A1 (en) Th1 cell adoptive immunotherapy
KR20120091012A (ko) 내추럴킬러 세포의 제조방법
US20030134341A1 (en) Th1 cell adoptive immunotherapy
Davis et al. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation
CN105969731B (zh) 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法
KR20230137392A (ko) 고도로 강력한 m-cenk 세포 및 방법
US20030194395A1 (en) Th1 cell adoptive immunotherapy
JP6782503B1 (ja) 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
HK40064965A (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
Tanzi et al. Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation
HK1240085B (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240085A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240616A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
EP3941487B1 (en) Cd28 t cell cultures, compositions, and methods of using thereof
HK40100476A (zh) 扩增t细胞群的方法
CN117120596A (zh) 高效的m-cenk细胞和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210405

R150 Certificate of patent or registration of utility model

Ref document number: 6865160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees